IN2015DN03925A - - Google Patents
Info
- Publication number
- IN2015DN03925A IN2015DN03925A IN3925DEN2015A IN2015DN03925A IN 2015DN03925 A IN2015DN03925 A IN 2015DN03925A IN 3925DEN2015 A IN3925DEN2015 A IN 3925DEN2015A IN 2015DN03925 A IN2015DN03925 A IN 2015DN03925A
- Authority
- IN
- India
- Prior art keywords
- antigens
- virus
- chimeric
- hcv
- vaccine compositions
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 241000711549 Hepacivirus C Species 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20120153A CU24112B1 (es) | 2012-11-05 | 2012-11-05 | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
| PCT/CU2013/000006 WO2014067498A1 (es) | 2012-11-05 | 2013-10-28 | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03925A true IN2015DN03925A (enExample) | 2015-10-02 |
Family
ID=49724426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3925DEN2015 IN2015DN03925A (enExample) | 2012-11-05 | 2013-10-28 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9676825B2 (enExample) |
| EP (1) | EP2915544B1 (enExample) |
| JP (1) | JP6259831B2 (enExample) |
| KR (1) | KR102093495B1 (enExample) |
| CN (1) | CN104837498B (enExample) |
| AR (1) | AR093341A1 (enExample) |
| AU (1) | AU2013339846B2 (enExample) |
| CA (1) | CA2901346C (enExample) |
| CU (1) | CU24112B1 (enExample) |
| ES (1) | ES2644801T3 (enExample) |
| IN (1) | IN2015DN03925A (enExample) |
| MX (1) | MX358507B (enExample) |
| RU (1) | RU2639504C2 (enExample) |
| WO (1) | WO2014067498A1 (enExample) |
| ZA (1) | ZA201503036B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10300131B2 (en) | 2015-07-07 | 2019-05-28 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
| WO2018055535A2 (en) * | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
| EP3618859A4 (en) | 2017-04-27 | 2021-05-05 | Vanderbilt University | HEPATITIS C VIRUS GENE SEQUENCES AND METHODS OF USE |
| US12048742B2 (en) | 2018-03-16 | 2024-07-30 | The Governors Of The University Of Alberta | Hepatitis C virus peptide compositions and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001037869A1 (en) * | 1999-11-19 | 2001-05-31 | Csl Limited | Vaccine compositions |
| US6544780B1 (en) * | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
| CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| ES2551113T3 (es) * | 2006-01-04 | 2015-11-16 | Glaxosmithkline Biologicals S.A. | Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC |
| US7256008B2 (en) | 2006-01-06 | 2007-08-14 | Abbott Laboratories | Determination of concentration of FK778 by competitive immunoassay |
| EP2222336A2 (en) * | 2007-10-29 | 2010-09-01 | GENimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
| WO2009131203A1 (ja) * | 2008-04-25 | 2009-10-29 | 東レ株式会社 | C型肝炎ウイルス由来のキメラ遺伝子を含む核酸 |
| US8728489B2 (en) * | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| US20110311550A1 (en) * | 2008-10-24 | 2011-12-22 | The Scripps Research Institute | Agents for hcv treatment |
-
2012
- 2012-11-05 CU CU20120153A patent/CU24112B1/es active IP Right Grant
-
2013
- 2013-10-28 KR KR1020157012656A patent/KR102093495B1/ko not_active Expired - Fee Related
- 2013-10-28 EP EP13801461.8A patent/EP2915544B1/en active Active
- 2013-10-28 ES ES13801461.8T patent/ES2644801T3/es active Active
- 2013-10-28 RU RU2015121429A patent/RU2639504C2/ru not_active IP Right Cessation
- 2013-10-28 CA CA2901346A patent/CA2901346C/en not_active Expired - Fee Related
- 2013-10-28 CN CN201380064380.9A patent/CN104837498B/zh not_active Expired - Fee Related
- 2013-10-28 US US14/440,443 patent/US9676825B2/en not_active Expired - Fee Related
- 2013-10-28 MX MX2015005651A patent/MX358507B/es active IP Right Grant
- 2013-10-28 JP JP2015540044A patent/JP6259831B2/ja not_active Expired - Fee Related
- 2013-10-28 AU AU2013339846A patent/AU2013339846B2/en not_active Ceased
- 2013-10-28 WO PCT/CU2013/000006 patent/WO2014067498A1/es not_active Ceased
- 2013-10-28 IN IN3925DEN2015 patent/IN2015DN03925A/en unknown
- 2013-11-04 AR ARP130104019A patent/AR093341A1/es unknown
-
2015
- 2015-05-04 ZA ZA2015/03036A patent/ZA201503036B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX358507B (es) | 2018-08-22 |
| ES2644801T3 (es) | 2017-11-30 |
| CN104837498A (zh) | 2015-08-12 |
| WO2014067498A1 (es) | 2014-05-08 |
| MX2015005651A (es) | 2015-08-20 |
| CU20120153A7 (es) | 2014-06-27 |
| RU2639504C2 (ru) | 2017-12-21 |
| AU2013339846B2 (en) | 2017-08-17 |
| US20150307558A1 (en) | 2015-10-29 |
| EP2915544B1 (en) | 2017-08-09 |
| RU2015121429A (ru) | 2016-12-27 |
| AU2013339846A1 (en) | 2015-05-14 |
| CA2901346C (en) | 2019-04-23 |
| ZA201503036B (en) | 2016-01-27 |
| JP2015536936A (ja) | 2015-12-24 |
| US9676825B2 (en) | 2017-06-13 |
| CA2901346A1 (en) | 2014-05-08 |
| JP6259831B2 (ja) | 2018-01-10 |
| AR093341A1 (es) | 2015-06-03 |
| CU24112B1 (es) | 2015-08-27 |
| CN104837498B (zh) | 2018-05-18 |
| KR102093495B1 (ko) | 2020-03-26 |
| KR20150079694A (ko) | 2015-07-08 |
| EP2915544A1 (en) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10288A (enExample) | ||
| PH12017500727A1 (en) | Modified virus-like particles of cmv | |
| PH12013501683A1 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
| MX364689B (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| MX342716B (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| PH12018501047A1 (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| IN2014KN03063A (enExample) | ||
| CA2898099C (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| MX2013002173A (es) | Formas farmaceuticas dirigidas de epitopos multiples para la induccion de una respuesta inmunologica frente a antigenos. | |
| WO2015134722A3 (en) | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio | |
| PH12016502554B1 (en) | A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection | |
| MX2013007918A (es) | Peptidos inmunogenicos monomericos y multimericos. | |
| MX391149B (es) | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. | |
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| IN2015DN03925A (enExample) | ||
| MX2019007924A (es) | Vacunas contra la influenza. | |
| IN2014DN09445A (enExample) | ||
| WO2014060851A3 (en) | Hepatitis c virus immunogenic compositions and methods of use thereof | |
| PH12017500816A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
| PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
| WO2016141201A3 (en) | Rational vaccine design for hepatitis c virus | |
| MX2016009952A (es) | Proteinas y antigenos del virus de diarrea epidemica porcino (pedv). | |
| MX365656B (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. | |
| WO2015171505A3 (en) | Antigens of pneumocystis murina and uses thereof | |
| MX2013009310A (es) | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica. |